PubRank

Christopher J Kirk

Author PubWeight™ 38.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007 3.85
2 A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009 2.62
3 Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011 2.56
4 Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 2012 2.03
5 Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012 1.83
6 Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 2009 1.67
7 The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 2012 1.52
8 Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009 1.50
9 Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010 1.36
10 Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011 1.35
11 A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010 1.25
12 Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 2008 1.14
13 PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2010 1.11
14 Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One 2011 1.10
15 Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol 2012 1.09
16 Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol 2011 1.04
17 Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012 1.02
18 Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle. Biochem J 2004 1.01
19 Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 2012 1.01
20 Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013 0.99
21 Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol 2013 0.98
22 Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 2014 0.95
23 Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res 2012 0.94
24 The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy 2012 0.92
25 Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol 2014 0.89
26 Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica 2013 0.89
27 The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 2011 0.85
28 Endocrine disrupting alkylphenols: structural requirements for their adverse effects on Ca2+ pumps, Ca2+ homeostasis & Sertoli TM4 cell viability. Chem Biol Interact 2008 0.83
29 Inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase by flavonoids: a quantitative structure-activity relationship study. IUBMB Life 2008 0.83
30 Alkylphenol endocrine disrupters inhibit IP3-sensitive Ca2+ channels. Biochem Biophys Res Commun 2003 0.75